Truvestments Capital LLC Invests $35,000 in The Chemours Company (NYSE:CC)

Truvestments Capital LLC bought a new stake in The Chemours Company (NYSE:CC) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,700 shares of the specialty chemicals company’s stock, valued at approximately $35,000.

Several other institutional investors and hedge funds have also bought and sold shares of CC. New Covenant Trust Company N.A. bought a new stake in shares of Chemours during the 1st quarter worth approximately $29,000. Blue Trust Inc. raised its position in Chemours by 166.9% during the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after acquiring an additional 731 shares in the last quarter. Matrix Trust Co acquired a new stake in Chemours in the third quarter valued at $25,000. Signaturefd LLC grew its position in shares of Chemours by 163.7% in the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company’s stock valued at $40,000 after acquiring an additional 1,216 shares during the period. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of Chemours during the 2nd quarter worth about $58,000. Institutional investors own 76.26% of the company’s stock.

Insiders Place Their Bets

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the sale, the senior vice president now directly owns 16,645 shares in the company, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.47% of the company’s stock.

Chemours Stock Down 0.5 %

CC stock opened at $21.82 on Thursday. The business’s fifty day moving average price is $19.53 and its two-hundred day moving average price is $21.39. The stock has a market capitalization of $3.26 billion, a price-to-earnings ratio of 42.96 and a beta of 1.75. The Chemours Company has a fifty-two week low of $15.10 and a fifty-two week high of $32.70. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92.

Chemours (NYSE:CC) last issued its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.44 billion. During the same quarter in the previous year, the company earned $0.64 EPS. The business’s revenue was up .9% on a year-over-year basis. On average, equities analysts anticipate that The Chemours Company will post 1.35 earnings per share for the current year.

Chemours Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 4.58%. The ex-dividend date is Friday, November 15th. Chemours’s dividend payout ratio is currently 200.00%.

Analysts Set New Price Targets

CC has been the subject of several recent analyst reports. JPMorgan Chase & Co. cut their target price on shares of Chemours from $25.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. Royal Bank of Canada reduced their target price on Chemours from $28.00 to $25.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Morgan Stanley decreased their target price on Chemours from $30.00 to $25.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 5th. Barclays raised their price target on Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Finally, BMO Capital Markets upped their price objective on shares of Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, October 7th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $24.88.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.